Global Personalized Medicine Biomarkers Market Size study & Forecast, by Indication (Oncology, Diabetes, Autoimmune Diseases, Cardiology, Others) by Application (Early Detection/Screening, Diagnosis, Treatment Selection, Monitoring) and Regional Analysis,

Global Personalized Medicine Biomarkers Market Size study & Forecast, by Indication (Oncology, Diabetes, Autoimmune Diseases, Cardiology, Others) by Application (Early Detection/Screening, Diagnosis, Treatment Selection, Monitoring) and Regional Analysis, 2022-2029

Global Personalized Medicine Biomarkers Market is valued at approximately USD 11.76 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 15.51% over the forecast period 2022-2029. Personalized medicine biomarkers are essential tools that are specially designed for the selection of suitable patients for treatment with certain drugs and allow them personalized medicine. It emphasizes on offering appropriate treatment to the right patient, at the right dose at the right time. The growing prevalence of chronic diseases, rising awareness and significance of analyzing the prognosis and selection of dose, and increasing requirement of providing early diagnosis and treatment are attributing to the market demand around the world.

The surging demand for personalized medicine is directly associated with the demand of personalized medicine biomarkers in the global market. As per Statista, it is estimated that the global market for personalized medicine was worth approximately USD 1,980 billion in 2019 and is expected to reach USD 2,770 billion by the year 2022. Accordingly, the increasing demand for personalized medicine is to create effective and safe therapies for every patient, thus, in turn, augmenting the growth of the market globally Moreover, growing investment in research & development activities, as well as technological advancements in the diagnosis and detection of chronic diseases, are presenting various lucrative opportunities over the forecasting years. However, the regulatory & reimbursement hurdles and the high capital investments and lengthy timelines for biomarker development are hampering challenging the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Personalized Medicine Biomarkers Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing availability of funding for biomarkers, increasing technological advancements, and the presence of key market players. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the availability of government funding and initiatives, growing healthcare reforms, as well as the rising usage of screening tests for cancer in the regional market space.

Major market players included in this report are:
Laboratory Corporation of America Holding
Quest Diagnostics Incorporated
Agilent Technologies, Inc.
Genome Medical, Inc.
Coriell Life Sciences.
Thermo Fisher Scientific Inc.
NeoGenomics Laboratories
Foundation Medicine, Inc.
Illumina, Inc.
Guardant Health

Recent Developments in the Market:
 In June 2022, GRAIL and AstraZeneca announced the companies entered a strategic partnership with the objective of creating companion diagnostic tests that facilitates the treatment of early-stage cancer.


Global Personalized Medicine Biomarkers Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Indication, Application, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.
The detailed segments and sub-segment of the market are explained below:

By Indication:
Oncology
Diabetes
Autoimmune Diseases
Cardiology
Others
By Application:
Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Laboratory Corporation of America Holding
Quest Diagnostics Incorporated
Agilent Technologies, Inc.
Genome Medical, Inc.
Coriell Life Sciences.
Thermo Fisher Scientific Inc.
NeoGenomics Laboratories
Foundation Medicine, Inc.
Illumina, Inc.
Guardant Health

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.